• Je něco špatně v tomto záznamu ?

Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor

JD. Melgarejo, L. Thijs, DM. Wei, M. Bursztyn, WY. Yang, Y. Li, K. Asayama, TW. Hansen, M. Kikuya, T. Ohkubo, E. Dolan, K. Stolarz-Skrzypek, YB. Cheng, V. Tikhonoff, S. Malyutina, E. Casiglia, L. Lind, E. Sandoya, J. Filipovský, K. Narkiewicz, N....

. 2021 ; 34 (9) : 929-938. [pub] 20210922

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003688

Grantová podpora
R01 AG036469 NIA NIH HHS - United States
R03 AG054186 NIA NIH HHS - United States

BACKGROUND: Pulse pressure (PP) reflects the age-related stiffening of the central arteries, but no study addressed the management of the PP-related risk over the human lifespan. METHODS: In 4,663 young (18-49 years) and 7,185 older adults (≥50 years), brachial PP was recorded over 24 hours. Total mortality and all major cardiovascular events (MACEs) combined were coprimary endpoints. Cardiovascular death, coronary events, and stroke were secondary endpoints. RESULTS: In young adults (median follow-up, 14.1 years; mean PP, 45.1 mm Hg), greater PP was not associated with absolute risk; the endpoint rates were ≤2.01 per 1,000 person-years. The adjusted hazard ratios expressed per 10-mm Hg PP increments were less than unity (P ≤ 0.027) for MACE (0.67; 95% confidence interval [CI], 0.47-0.96) and cardiovascular death (0.33; 95% CI, 0.11-0.75). In older adults (median follow-up, 13.1 years; mean PP, 52.7 mm Hg), the endpoint rates, expressing absolute risk, ranged from 22.5 to 45.4 per 1,000 person-years and the adjusted hazard ratios, reflecting relative risk, from 1.09 to 1.54 (P < 0.0001). The PP-related relative risks of death, MACE, and stroke decreased >3-fold from age 55 to 75 years, whereas absolute risk rose by a factor 3. CONCLUSIONS: From 50 years onwards, the PP-related relative risk decreases, whereas absolute risk increases. From a lifecourse perspective, young adulthood provides a window of opportunity to manage risk factors and prevent target organ damage as forerunner of premature death and MACE. In older adults, treatment should address absolute risk, thereby extending life in years and quality.

1st Department of Cardiology Interventional Electrocardiology and Hypertension Jagiellonian University Medical College Kraków Poland

Alzheimer's Disease Resource Center for Minority Aging Research University of Texas Rio Grande Valley Brownsville Texas USA

Asociación Española Primera de Socorros Mutuos Montevideo Uruguay

Biomedical Science Group Faculty of Medicine University of Leuven Leuven Belgium

Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation Shanghai Institute of Hypertension Shanghai Key Laboratory of Hypertension Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China

Centre for Molecular and Vascular Biology KU Leuven Department of Cardiovascular Sciences University of Leuven Leuven Belgium

Centro de Nefrología and Departamento de Fisiopatología Hospital de Clínicas Universidad de la República Montevideo Uruguay

Conway Institute University College Dublin Dublin Ireland

Department of Cardiology Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

Department of Human Genetics University of Texas Rio Grande Valley School of Medicine Brownsville Texas USA

Department of Hygiene and Public Health Teikyo University School of Medicine Tokyo Japan

Department of Hypertension Medical University of Gdańsk Gdańsk Poland

Department of Medicine University of Padova Padova Italy

Department of Neurosciences University of Texas Rio Grande Valley School of Medicine Brownsville Texas USA

Division of Cardiology Department of Internal Medicine University Hospitals Leuven Leuven Belgium

Faculty of Medicine Charles University Pilsen Czech Republic

Faculty of Medicine Hebrew University Department of Internal Medicine Hadassah Hebrew University Medical Center Jerusalem Israel

Institute of Internal and Preventive Medicine Internal and Preventive Medicine Branch of the Institute of Cytology and Genetics Siberian Branch of the Russian Academy of Science Novosibirsk Russian Federation

Laboratory of Neurosciences Faculty of Medicine University of Zulia Maracaibo Zulia Venezuela

Research Institute Alliance for the Promotion of Preventive Medicine Mechelen Belgium

Research Unit Hypertension and Cardiovascular Epidemiology KU Leuven Department of Cardiovascular Sciences University of Leuven Leuven Belgium

Section of Geriatrics Department of Public Health and Caring Sciences Uppsala University Uppsala Sweden

Steno Diabetes Center Copenhagen Gentofte and Center for Clinical Research and Prevention Bispebjerg and Frederiksberg Hospital Frederiksberg Denmark

Stroke and Hypertension Unit Blanchardstown Dublin Ireland

Tohoku Institute for Management of Blood Pressure Sendai Japan

Yazmonit Ltd Jerusalem Israel

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003688
003      
CZ-PrNML
005      
20220127150001.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ajh/hpab048 $2 doi
035    __
$a (PubMed)33687055
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Melgarejo, Jesus D $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium $u Laboratory of Neurosciences, Faculty of Medicine, University of Zulia, Maracaibo, Zulia, Venezuela
245    10
$a Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor / $c JD. Melgarejo, L. Thijs, DM. Wei, M. Bursztyn, WY. Yang, Y. Li, K. Asayama, TW. Hansen, M. Kikuya, T. Ohkubo, E. Dolan, K. Stolarz-Skrzypek, YB. Cheng, V. Tikhonoff, S. Malyutina, E. Casiglia, L. Lind, E. Sandoya, J. Filipovský, K. Narkiewicz, N. Gilis-Malinowska, K. Kawecka-Jaszcz, J. Boggia, JG. Wang, Y. Imai, P. Verhamme, S. Trenson, S. Janssens, E. O'Brien, GE. Maestre, B. Gavish, JA. Staessen, ZY. Zhang
520    9_
$a BACKGROUND: Pulse pressure (PP) reflects the age-related stiffening of the central arteries, but no study addressed the management of the PP-related risk over the human lifespan. METHODS: In 4,663 young (18-49 years) and 7,185 older adults (≥50 years), brachial PP was recorded over 24 hours. Total mortality and all major cardiovascular events (MACEs) combined were coprimary endpoints. Cardiovascular death, coronary events, and stroke were secondary endpoints. RESULTS: In young adults (median follow-up, 14.1 years; mean PP, 45.1 mm Hg), greater PP was not associated with absolute risk; the endpoint rates were ≤2.01 per 1,000 person-years. The adjusted hazard ratios expressed per 10-mm Hg PP increments were less than unity (P ≤ 0.027) for MACE (0.67; 95% confidence interval [CI], 0.47-0.96) and cardiovascular death (0.33; 95% CI, 0.11-0.75). In older adults (median follow-up, 13.1 years; mean PP, 52.7 mm Hg), the endpoint rates, expressing absolute risk, ranged from 22.5 to 45.4 per 1,000 person-years and the adjusted hazard ratios, reflecting relative risk, from 1.09 to 1.54 (P < 0.0001). The PP-related relative risks of death, MACE, and stroke decreased >3-fold from age 55 to 75 years, whereas absolute risk rose by a factor 3. CONCLUSIONS: From 50 years onwards, the PP-related relative risk decreases, whereas absolute risk increases. From a lifecourse perspective, young adulthood provides a window of opportunity to manage risk factors and prevent target organ damage as forerunner of premature death and MACE. In older adults, treatment should address absolute risk, thereby extending life in years and quality.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a rizikové faktory kardiovaskulárních chorob $7 D000082742
650    _2
$a lidé $7 D006801
650    12
$a hypertenze $x prevence a kontrola $7 D006973
650    _2
$a lidé středního věku $7 D008875
650    _2
$a riziko $7 D012306
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Thijs, Lutgarde $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
700    1_
$a Wei, Dong-Mei $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
700    1_
$a Bursztyn, Michael $u Faculty of Medicine, Hebrew University, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
700    1_
$a Yang, Wen-Yi $u Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
700    1_
$a Li, Yan $u Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
700    1_
$a Asayama, Kei $u Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan $u Tohoku Institute for Management of Blood Pressure, Sendai, Japan
700    1_
$a Hansen, Tine W $u Steno Diabetes Center Copenhagen, Gentofte and Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark
700    1_
$a Kikuya, Masahiro $u Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan
700    1_
$a Ohkubo, Takayoshi $u Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan $u Tohoku Institute for Management of Blood Pressure, Sendai, Japan
700    1_
$a Dolan, Eamon $u Stroke and Hypertension Unit, Blanchardstown, Dublin, Ireland
700    1_
$a Stolarz-Skrzypek, Katarzyna $u First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland
700    1_
$a Cheng, Yi-Bang $u Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
700    1_
$a Tikhonoff, Valérie $u Department of Medicine, University of Padova, Padova, Italy
700    1_
$a Malyutina, Sofia $u Institute of Internal and Preventive Medicine, Internal and Preventive Medicine-Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science, Novosibirsk, Russian Federation
700    1_
$a Casiglia, Edoardo $u Department of Medicine, University of Padova, Padova, Italy
700    1_
$a Lind, Lars $u Section of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
700    1_
$a Sandoya, Edgardo $u Asociación Española Primera de Socorros Mutuos, Montevideo, Uruguay
700    1_
$a Filipovský, Jan $u Faculty of Medicine, Charles University, Pilsen, Czech Republic
700    1_
$a Narkiewicz, Krzysztof $u Department of Hypertension, Medical University of Gdańsk, Gdańsk, Poland
700    1_
$a Gilis-Malinowska, Natasza $u Department of Hypertension, Medical University of Gdańsk, Gdańsk, Poland
700    1_
$a Kawecka-Jaszcz, Kalina $u First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland
700    1_
$a Boggia, José $u Centro de Nefrología and Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay
700    1_
$a Wang, Ji-Guang $u Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
700    1_
$a Imai, Yutaka $u Tohoku Institute for Management of Blood Pressure, Sendai, Japan
700    1_
$a Verhamme, Peter $u Centre for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
700    1_
$a Trenson, Sander $u Division of Cardiology, Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Janssens, Stefan $u Division of Cardiology, Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium
700    1_
$a O'Brien, Eoin $u Conway Institute, University College Dublin, Dublin, Ireland
700    1_
$a Maestre, Gladys E $u Laboratory of Neurosciences, Faculty of Medicine, University of Zulia, Maracaibo, Zulia, Venezuela $u Department of Neurosciences, University of Texas Rio Grande Valley School of Medicine, Brownsville, Texas, USA $u Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine, Brownsville, Texas, USA $u Alzheimer's Disease Resource Center for Minority Aging Research, University of Texas Rio Grande Valley, Brownsville, Texas, USA
700    1_
$a Gavish, Benjamin $u Yazmonit Ltd., Jerusalem, Israel
700    1_
$a Staessen, Jan A $u Research Institute Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium $u Biomedical Science Group, Faculty of Medicine, University of Leuven, Leuven, Belgium
700    1_
$a Zhang, Zhen-Yu $u Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
773    0_
$w MED00000255 $t American journal of hypertension $x 1941-7225 $g Roč. 34, č. 9 (2021), s. 929-938
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33687055 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145958 $b ABA008
999    __
$a ok $b bmc $g 1751211 $s 1154837
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 34 $c 9 $d 929-938 $e 20210922 $i 1941-7225 $m American journal of hypertension $n Am J Hypertens $x MED00000255
GRA    __
$a R01 AG036469 $p NIA NIH HHS $2 United States
GRA    __
$a R03 AG054186 $p NIA NIH HHS $2 United States
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace